Abstract: Use of microcystins having a monocyclic heptapeptide structure in preparation of drugs for preventing or treating organ and tissue fibrosis diseases. Preferably, the microcystins are microcystin-LR with amino acids at positions 2 and 4 of a monocyclic heptapeptide structure thereof being leucine and arginine respectively, or are microcystin-RR with amino acids at positions 2 and 4 thereof being both arginine. Also provided is a method for inhibiting myofibroblast differentiation and collagen synthesis. The method is implemented by inhibiting a TGF-?/Smad signaling pathway by using one or more microcystins.

Abstract: A gas-liquid dynamic model-based accurate lithium-ion battery SOC estimation method, the gas-liquid dynamic model being a cylindrical closed container, a pipe and a valve that can be opened or closed being mounted at the top of the container, a liquid having a volume of Vw being held in the cylindrical container, and the remaining volume, V, being the volume of a gas having a pressure of P. According to the accurate SOC estimation method, a model, different from conventional RC equivalent circuit model and electrochemical model, is established from the perspective of a gas-liquid coexistence system. The method comprises the following steps: setting up an ideal gas state equation, a gas continuous motion equation, a gas-liquid dissolution equilibrium equation, etc.

Abstract: The present invention provides a system for supplying heat by means of stratum coal in-place slurrying and a method for supplying power generation heat by means of stratum coal in-place slurrying, belonging to the technical field of ground-source well heat exchange. The system comprises a stratum coal slurrying device, a mid-deep well casing device and a heat exchange device. The stratum coal slurrying device comprises a water inlet pump and a coal slurry pump, which are connected to a directional slurry preparing drill through pipelines, respectively. The mid-deep well casing device comprises a vertically buried pipe, and a heat-insulating inner pipe that is coaxial with the vertically buried pipe and inserted into the vertically buried pipe. A microporous pipe assembly is arranged on the bottom of the heat-insulating inner pipe.

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

Abstract: The present invention provides a system for supplying heat by means of stratum coal in-place slurrying and a method for supplying power generation heat by means of stratum coal in-place slurrying, belonging to the technical field of ground-source well heat exchange. The system comprises a stratum coal slurrying device, a mid-deep well casing device and a heat exchange device. The stratum coal slurrying device comprises a water inlet pump and a coal slurry pump, which are connected to a directional slurry preparing drill through pipelines, respectively. The mid-deep well casing device comprises a vertically buried pipe, and a heat-insulating inner pipe that is coaxial with the vertically buried pipe and inserted into the vertically buried pipe. A microporous pipe assembly is arranged on the bottom of the heat-insulating inner pipe.

Abstract: A gas-liquid dynamic model-based accurate lithium-ion battery SOC estimation method, the gas-liquid dynamic model being a cylindrical closed container, a pipe and a valve that can be opened or closed being mounted at the top of the container, a liquid having a volume of Vw being held in the cylindrical container, and the remaining volume, V, being the volume of a gas having a pressure of P. According to the accurate SOC estimation method, a model, different from conventional RC equivalent circuit model and electrochemical model, is established from the perspective of a gas-liquid coexistence system. The method comprises the following steps: setting up an ideal gas state equation, a gas continuous motion equation, a gas-liquid dissolution equilibrium equation, etc.

Abstract: This disclosure provides wafer dicing methods, and relates to the field of semiconductor technologies. Implementations of the dicing method may include: performing laser stealth dicing processing on a wafer from a back surface of the wafer; performing grinding and thinning processing on the back surface of the wafer after performing the laser stealth dicing processing; sticking a dicing tape on the back surface of the wafer after performing the grinding and thinning processing; and performing separation processing on the wafer after sticking the dicing tape. In some implementations, stealth dicing (SD) is performed before grinding, so that a laser is directly imposed on a back surface of a wafer, thereby alleviating a laser attenuation problem and lowering requirements on light transmittance of a dicing tape.

Abstract: A grinding mechanism is provided including a support table configured for fixing a workpiece to be ground thereon, and a sliding assembly slidably provided on the support table and including a cleaning tool. The cleaning tool includes a scraper configured to face the support table and a scraper holder to which the scraper is provided.

Abstract: Use of microcystins having a monocyclic heptapeptide structure in preparation of drugs for preventing or treating organ and tissue fibrosis diseases. Preferably, the microcystins are microcystin-LR with amino acids at positions 2 and 4 of a monocyclic heptapeptide structure thereof being leucine and arginine respectively, or are microcystin-RR with amino acids at positions 2 and 4 thereof being both arginine. Also provided is a method for inhibiting myofibroblast differentiation and collagen synthesis. The method is implemented by inhibiting a TGF-?/Smad signaling pathway by using one or more microcystins.

Abstract: This disclosure provides wafer dicing methods, and relates to the field of semiconductor technologies. Implementations of the dicing method may include: performing laser stealth dicing processing on a wafer from a back surface of the wafer; performing grinding and thinning processing on the back surface of the wafer after performing the laser stealth dicing processing; sticking a dicing tape on the back surface of the wafer after performing the grinding and thinning processing; and performing separation processing on the wafer after sticking the dicing tape. In some implementations, stealth dicing (SD) is performed before grinding, so that a laser is directly imposed on a back surface of a wafer, thereby alleviating a laser attenuation problem and lowering requirements on light transmittance of a dicing tape.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The present invention provides a new method for synthesizing maxacalcitol and an intermediate thereof. According to the method, the maxacalcitol is creatively synthesized through the steps of: taking vitamin D2 as an initial raw material, obtaining a compound represented by formula II, oxidizing, chirally reducing, grafting with a side chain, introducing a hydroxyl group on the C-1 position, and photochemically overturning.

Abstract: Phenyl propanoic acid compounds having activating effect on peroxisome proliferator-activated receptors (PPAR?,?,?) and a preparation method and uses thereof are provided in the present invention. The compounds can be used for treating or preventing diseases associated with peroxisome proliferator-activated receptors (PPAR?,?,?).

Abstract: The invention is directed to novel pyrrolopyrimidine compounds of formula (1) wherein R1, R2y, R4, R8-R11, A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CDK4/6 activity and to the treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.